Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation

Kidney International

Volumn 94, Issue 1, 2018, Pages 114-125

  Liu, Pan ^a   Wysocki, Jan ^a   Souma, Tomokazu ^a   Ye, Minghao ^a   Ramirez, Veronica ^a   Zhou, Bisheng ^a   Wilsbacher, Lisa D ^a   Quaggin, Susan E ^a   Batlle, Daniel ^a   Jin, Jing ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

angiotensin 1 7; angiotensin II; angiotensin converting enzyme 2; Fc fusion; hypertension; proteinuria; renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CHIMERIC PROTEIN; FUSION PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDASE; RENIN; DIPEPTIDYL CARBOXYPEPTIDASE;

ALBUMINURIA; ANGIOTENSIN BLOOD LEVEL; ANGIOTENSIN II BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; ELIMINATION HALF-LIFE; ENZYME ACTIVITY; FEMALE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY FIBROSIS; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; DISEASE MODEL; GENETICS; HALF LIFE TIME; ISOLATION AND PURIFICATION; TREATMENT OUTCOME;

ANGIOTENSIN II; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; HALF-LIFE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, INBRED BALB C; PEPTIDYL-DIPEPTIDASE A; RECOMBINANT FUSION PROTEINS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 85046120145     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2018.01.029     Document Type: Article

References (62)

1. Romero, C.A., Orias, M., Weir, M.R., Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol 11 (2015), 242–252.
2. Raij, L., The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens 18 (2005), 95S–99S.
3. Varagic, J., Ahmad, S., Nagata, S., et al. ACE2: angiotensin II/angiotensin-(1–7) balance in cardiac and renal injury. Curr Hypertens Rep, 16, 2014, 420.
4. Batlle, D., Wysocki, J., Soler, M.J., et al. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int 81 (2012), 520–528.
5. Batlle, D., Soler, M.J., Wysocki, J., New aspects of the renin–angiotensin system: angiotensin-converting enzyme 2 – a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 17 (2008), 250–257.
6. Welches, W.R., Bridget Brosnihan, K., Ferrario, C.M., A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 52 (1993), 1461–1480.
7. Chappell, M.C., Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?. Am J Physiol Heart Circ Physiol 310 (2016), H137–H152.
8. Santos, R.A.S., Ferreira, A.J., Verano-Braga, T., et al. Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216 (2013), R1–R17.
9. Chappell, M., Marshall, A., Alzayadneh, E., et al. Update on the angiotensin converting enzyme 2-angiotensin (1–7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol, 4, 2014, 201.
10. Ross, M.J., Nangaku, M., ACE2 as therapy for glomerular disease: the devil is in the detail. Kidney Int 91 (2017), 1269–1271.
11. Bae, E.H., Fang, F., Williams, V.R., et al. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome. Kidney Int 91 (2017), 1347–1361.
12. Wysocki, J., Ye, M., Khattab, A.M., et al. Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. Kidney Int 91 (2016), 1336–1346.
13. Ye, M., Wysocki, J., William, J., et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17 (2006), 3067–3075.
14. Gu, H., Xie, Z., Li, T., et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep, 6, 2016, 19840.
15. Imai, Y., Kuba, K., Rao, S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436 (2005), 112–116.
16. Zou, Z., Yan, Y., Shu, Y., et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun, 5, 2014, 3594.
17. Rey-Parra, G.J., Vadivel, A., Coltan, L., et al. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J Mol Med 90 (2012), 637–647.
18. Wysocki, J., Ye, M., Rodriguez, E., et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2:prevention of angiotensin II-dependent hypertension. Hypertension 55 (2010), 90–98.
19. Ye, M., Wysocki, J., Gonzalez-Pacheco, F.R., et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 60 (2012), 730–740.
20. Zhong, J., Basu, R., Guo, D., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728.
21. Huentelman, M.J., Grobe, J.L., Vazquez, J., et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90 (2005), 783–790.
22. Zhong, J., Guo, D., Chen, C.B., et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57 (2011), 314–322.
23. Chen, L.-J., Xu, Y.-L., Song, B., et al. Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR/ERK signaling in apolipoprotein E-deficient mice. Peptides 79 (2016), 49–57.
24. Haschke, M., Schuster, M., Poglitsch, M., et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52 (2013), 783–792.
25. Li, X., Molina-Molina, M., Abdul-Hafez, A., et al. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 295 (2008), L178–L185.
26. Yamazato, Y., Ferreira, A.J., Hong, K.-H., et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 54 (2009), 365–371.
27. Nadarajah, R., Milagres, R., Dilauro, M., et al. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82 (2012), 292–303.
28. Czajkowsky, D.M., Hu, J., Shao, Z., et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 4 (2012), 1015–1028.
29. Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7 (2007), 715–725.
30. Dall'Acqua, W.F., Kiener, P.A., Wu, H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281 (2006), 23514–23524.
31. Rath, T., Baker, K., Dumont, J.A., et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 35 (2015), 235–254.
32. Yousefpour, P., Chilkoti, A., Co-opting biology to deliver drugs. Biotechnol Bioeng 111 (2014), 1699–1716.
33. Kontermann, R.E., Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22 (2011), 868–876.
34. Fisher, C.J. Jr., Agosti, J.M., Opal, S.M., et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl J Med 334 (1996), 1697–1702.
35. Ellis, C.N., Krueger, G.G., Alefacept Clinical Study G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001), 248–255.
36. Genovese, M.C., Becker, J.C., Schiff, M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005), 1114–1123.
37. Strohl, W.R., Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29 (2015), 215–239.
38. Rice, G.I., Jones, A.L., Grant, P.J., et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48 (2006), 914–920.
39. Elased, K.M., Cunha, T.S., Gurley, S.B., et al. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension 47 (2006), 1010–1017.
40. Liu, P., Wysocki, J., Serfozo, P., et al. A fluorometric method of measuring carboxypeptidase activities for angiotensin ii and apelin-13. Sci Rep, 7, 2017, 45473.
41. Oudit, G.Y., Liu, G.C., Zhong, J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59 (2010), 529–538.
42. Blumberg, R.S., Koss, T., Story, C.M., et al. A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 95 (1995), 2397–2402.
43. Caron, K.M.I., James, L.R., Kim, H.-S., et al. A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci U S A 99 (2002), 8248–8252.
44. Caron, K.M.I., James, L.R., Kim, H.-S., et al. Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proc Natl Acad Sci U S A 101 (2004), 3106–3111.
45. Wang, J., Chen, L., Chen, B., et al. Chronic activation of the renin-angiotensin system induces lung fibrosis. Sci Rep, 5, 2015, 15561.
46. Huby, A.-C., Kavvadas, P., Alfieri, C., et al. The RenTg mice: a powerful tool to study renin-dependent chronic kidney disease. PLoS One, 7, 2012, e52362.
47. Yu, J., Lubinsky, D., Tsomaia, N., et al. Activation of ERK, JNK, Akt, and G-protein coupled signaling by hybrid angiotensin II AT1/bradykinin B2 receptors expressed in HEK-293 cells. J Cell Biochem 101 (2007), 192–204.
48. Shen, Y., Cheng, F., Sharma, M., et al. Granzyme B deficiency protects against angiotensin II-induced cardiac fibrosis. Am J Pathol 186 (2016), 87–100.
49. Jackson, T.R., Blair, L.A., Marshall, J., et al. The mas oncogene encodes an angiotensin receptor. Nature 335 (1988), 437–440.
50. Santos, R.A., Simoes e Silva, A.C., Maric, C., et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003), 8258–8263.
51. Chappell, M.C., Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 50 (2007), 596–599.
52. Grobe, J.L., Mecca, A.P., Lingis, M., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol 292 (2007), H736–H742.
53. Pereira, R.M., Dos Santos, R.A., Teixeira, M.M., et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of angiotensin-(1–7). J Hepatol 46 (2007), 674–681.
54. Chen, Q., Yang, Y., Huang, Y., et al. Angiotensin-(1–7) attenuates lung fibrosis by way of Mas receptor in acute lung injury. J Surg Res 185 (2013), 740–747.
55. Shapiro, A., Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin Biol Ther 13 (2013), 1287–1297.
56. Collins, P., Chalmers, E., Chowdary, P., et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 22 (2016), 487–498.
57. Yamaleyeva, L.M., Pulgar, V.M., Lindsey, S.H., et al. Uterine artery dysfunction in pregnant ACE2 knockout mice is associated with placental hypoxia and reduced umbilical blood flow velocity. Am J Physiol Endocrinol Metab 309 (2015), E84–E94.
58. Anton, L., Merrill, D.C., Neves, L.A.A., et al. Activation of local chorionic villi angiotensin II levels but not angiotensin (1–7) in preeclampsia. Hypertension 51 (2008), 1066–1072.
59. Bharadwaj, M.S., Strawn, W.B., Groban, L., et al. Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension 58 (2011), 852–858.
60. Cooper, W.O., Hernandez-Diaz, S., Arbogast, P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 (2006), 2443–2451.
61. Bullo, M., Tschumi, S., Bucher, B.S., et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60 (2012), 444–450.
62. Petrie, M.C., Padmanabhan, N., McDonald, J.E., et al. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37 (2001), 1056–1061.